Gut microbiota modulate dendritic cell antigen presentation and radiotherapy-induced antitumor immune response
Open accessThe DOI matches its Crossref record; 78 of the 79 references it cites were found in a registry or an index.
Abstract
Alterations in gut microbiota impact the pathophysiology of several diseases, including cancer. Radiotherapy (RT), an established curative and palliative cancer treatment, exerts potent immune modulatory effects, inducing tumor-associated antigen (TAA) cross-priming with antitumor CD8+ T cell elicitation and abscopal effects. We tested whether the gut microbiota modulates antitumor immune response following RT distal to the gut. Vancomycin, an antibiotic that acts mainly on gram-positive bacteria and is restricted to the gut, potentiated the RT-induced antitumor immune response and tumor growth inhibition. This synergy was dependent on TAA cross presentation to cytolytic CD8+ T cells and on IFN-γ. Notably, butyrate, a metabolite produced by the vancomycin-depleted gut bacteria, abrogated the vancomycin effect. In conclusion, depletion of vancomycin-sensitive bacteria enhances the antitumor activity of RT, which has important clinical ramifications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In mouse models, certain gut commensals mediate efficacy of anticancer therapies, including chemotherapy, radiotherapy, and immunotherapies such as adoptive T cell transfer, intratumoral CpG-oligonucleotides, and ICIs.”
From Melanoma and microbiota: Current understanding and future directions (2024) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“High serum levels of butyrate and propionate have been associated with resistance to anti-CTLA-4 antibodies and radiotherapy and increased Treg cell numbers in patients with melanoma.”
From Melanoma and microbiota: Current understanding and future directions (2024) · cites this paper as [7]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“whereas some studies found that gut commensals were able to impact tumor growth independently [33, 138].”
From Gut microbiota-mediated immunomodulation in tumor (2021) · cites this paper as [138]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
QIIME allows analysis of high-throughput community sequencing data
Caporaso, J. G., Kuczynski, J., Stombaugh, J., Bittinger, K., Bushman, F. D., Costello, E. K., Fierer, N., Peña, A. G., Goodrich, J. K., Gordon, J. I., et al. (2010) · Nature Methods · doi:10.1038/nmeth.f.303 · Cited by 34,887
Self-citationSearch and clustering orders of magnitude faster than BLAST
Edgar, R. C. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq461 · Cited by 20,826
FastTree 2 – Approximately Maximum-Likelihood Trees for Large Alignments
Price, M. N., Dehal, P. S., & Arkin, A. P. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009490 · Cited by 14,894 · cited 3×
“FastTree 2--approximately maximum-likelihood trees for large alignments.”
MethodUniFrac: a New Phylogenetic Method for Comparing Microbial Communities
Lozupone, C., & Knight, R. (2005) · Applied and Environmental Microbiology · doi:10.1128/aem.71.12.8228-8235.2005 · Cited by 8,227 · cited 1×
“(77) were computed between each pair of samples using QIIME.”
MethodGut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671
Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells
Furusawa, Y., Obata, Y., Fukuda, S., Endo, T. A., Nakato, G., Takahashi, D., Nakanishi, Y., Uetake, C., Kato, K., Kato, T., et al. (2013) · Nature · doi:10.1038/nature12721 · Cited by 5,549 · cited 1×
“SCFAs produced by colonic Clostridia were also shown to induce the differentiation of colonic Treg cells in mice (68).”
BackgroundRole of the microbiota in immunity and inflammation.
Belkaid, Y., & Hand, T. W. (2014) · Cell · doi:10.1016/j.cell.2014.03.011 · Cited by 5,385
den Besten, G., van Eunen, K., Groen, A. K., Venema, K., Reijngoud, D.-J., & Bakker, B. M. (2013) · Journal of Lipid Research · doi:10.1194/jlr.r036012 · Cited by 5,048
Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation
Arpaia, N., Campbell, C., Fan, X., Dikiy, S., van der Veeken, J., deRoos, P., Liu, H., Cross, J. R., Pfeffer, K., Coffer, P. J., et al. (2013) · Nature · doi:10.1038/nature12726 · Cited by 4,838 · cited 1×
“Although DCs can also modulate T cells in a butyrate-dependent manner (67), to our knowledge, the direct impact on antigen presentation in the context of RT has not been investigated.”
BackgroundGut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812
Research works printed but not linked: 1
- 10.1038/nature14292 · DOI · Paper page
Cited by
Items 201–300 of 316
Interaction of microbiome and immunity in tumorigenesis and clinical treatment
Yu, Y., & Zhong, W. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113894 · Cited by 10
Ma, C., Awosika, J. A., B., M. C. M., Coffman, K., Xie, C., Skorupan, N., Hrones, D. M., Liu, M., Ma, L., Wood, B. J., et al. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217975 · Cited by 11
Unveiling the interplay between microbiota and PD1/PD-L1 axis in tumor immunity and immunotherapy
Lu, Q., Wu, J., Yu, X., Qian, J., & Song, Z. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1690374 · Cited by 6
Microbial-Derived Metabolites and Their Impact on Cancer Immunotherapy
Jeong, J., Baines, K. J., & Vareki, S. M. (2026) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-25-1018 · Cited by 9
Wu, B., Quan, C., He, Y., Matsika, J., Huang, J., Liu, B., & Chen, J. (2024) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2024.2371543 · Cited by 7
“At the same time, it enhanced the presentation of antigens by CD11c+ DC in the tumor-draining lymph nodes of mice [56].”
Leveraging gut microbiota for enhanced immune checkpoint blockade in solid tumor therapy
Hu, J., Feng, T., Zhang, L., Zhou, Q., & Zhu, L. (2025) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003687 · Cited by 8
“[46] The Bifidobacteriaceae family activates DCs’ G protein-coupled receptor (GPR) 43 through butyrate, thereby inducing DCs maturation, enhancing their antigen-presenting ability, stimulating the secretion of interleukin-12 (IL-12), and ultimately enhancing the anti-tumor activity of CD8 + T cells…”
He, Y. M., Li, X., Hu, A.-Q., & Qian, D. (2024) · Journal of Oral Microbiology · doi:10.1080/20002297.2024.2359887 · Cited by 5
“Vancomycin potentiated the radiotherapy-induced antitumor immune response and tumor growth inhibition dependent on cytolytic CD8+ T cell/IFNγ elicitation and the abscopal effect [25,51].”
BackgroundMohammad, S. I., Hammood, Y. M., Vasudevan, A., Uthirapathy, S., Ballal, S., Sabarivani, A., Mishra, S., Nathiya, D., Al‐qaim, Z. H., & KADHIM, A. J. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05447-7 · Cited by 7
“SCFAs, for instance, play a significant role in modulating mucosal immunity, antigen presentation, and overall immune responses [87].”
Gut microbiota drives cancer evolution and therapy resistance
Min, S., Zhang, Y., Zhang, H., & Liu, Q. (2026) · Molecular Cancer · doi:10.1186/s12943-025-02564-8 · Cited by 10
“Recent evidence indicates a potential association between the GM and the efficacy of radiotherapy, including its capacity to modulate anti-cancer immune responses at sites distal to the intestine following treatment [182].”
How do tumours outside the gastrointestinal tract respond to dietary fibre supplementation?
Asim, F., Clarke, L., Donnelly, E., Jamal, F. R., Piccicacchi, L. M., Qadir, M., Raja, N. T., Samadi, C., Then, C. K., & Kiltie, A. E. (2023) · BMJ Oncology · doi:10.1136/bmjonc-2023-000107 · Cited by 5
“…in the gut, has been shown to enhance radiotherapy efficacy via increasing dendritic cell antigen presentation in preclinical melanoma and lung/ cervical tumour models, 7 although an antibiotic cock-tail of ampicillin, imipenem, cilastatin and vancomycin reduced tumour response to radiotherapy.”
BackgroundWen, X., Ye, X., Yang, X., RuJin, J., Qian, C., & Wang, X. (2022) · Clinical & Translational Oncology · doi:10.1007/s12094-022-02995-5 · Cited by 5
“Still, other research demonstrated that intestinal commensals could influence tumor development independently [114, 115].”
ResultLim, E. S. Y., Ong, Y., Chou, Y., & Then, C. K. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104468 · Cited by 6
The Role of the Microbiome in Cancer Therapies
Chalif, J., Goldstein, N. E. S., Mehra, Y., Spakowicz, D. J., & Chambers, L. (2025) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2024.12.005 · Cited by 7
Kumazoe, M., Takamatsu, K., Horie, F., Yoshitomi, R., Hamagami, H., TANAKA, H. L., Fujimura, Y., & Tachibana, H. (2021) · Scientific Reports · doi:10.1038/s41598-021-02346-4 · Cited by 5
The microbiome and precision oncology: an emerging paradigm in anticancer therapy
Bhat, S. A., Kaur, R., Chauhan, A., & Pal, A. (2022) · Critical Reviews in Microbiology · doi:10.1080/1040841x.2022.2035313 · Cited by 8
“(2020), for the first time, published a mechanistic study revealing a previously unknown role of the microbiome in radiotherapy response in melanoma, lung, and renal cancer models (Uribe-Herranz et al. 2020).”
BackgroundInfluentialThe Microbiome: the Link to Colorectal Cancer and Research Opportunities
Cass, S. H., Ajami, N. J., & White, M. G. (2022) · Current Treatment Options in Oncology · doi:10.1007/s11864-022-00960-6 · Cited by 5
Montero, B. K., Wasimuddin, Schwensow, N., Gillingham, M. A. F., Ratovonamana, Y. R., Rakotondranary, S. J., Corman, V. M., Drosten, C., Ganzhorn, J. U., & Sommer, S. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.06.01.446545 · Cited by 5
Then, C. K., Paillas, S., Moomin, A., Misheva, M., Moir, R., Hay, S., Bremner, D. M., Nellany, K., SMITH, E., Heidari, Z., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-2686427/v1 · Cited by 5
Microbiome-mediated regulation of chemoradiotherapy response
Lan, Z., Li, B., Ren, J., Wang, S., & Wang, J. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1659467 · Cited by 6
Capelletti, M. M., Montini, O., Ruini, E., Tettamanti, S., Savino, A. M., & Sarno, J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms26010045 · Cited by 5
“Notably, the microbiome plays a role in regulating the immune system’s antitumour responses to different types of therapeutic strategies, such as chemotherapy [224], radiotherapy [225,226], immune checkpoint inhibition [227], adoptive cell therapy [228] and CAR T cell therapy [229,230].”
Ma, F., Miao, X., Lin, Y., Luo, X., Chen, T., Ni, Z., & Wang, X. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114498 · Cited by 4
Palkovský, M., Modráčková, N., Bunešová, V., Liberko, M., & Soumarová, R. (2024) · In Vivo · doi:10.21873/invivo.13803 · Cited by 8
Immunotherapy and radiotherapy: An effective combination in cancer treatment
Li, X., Wang, C., Yang, H., Xue, W., Ding, Y.-Q., Wu, N., Pei, B., Ma, X., & Yang, W. (2025) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003609 · Cited by 5
“Such a study would help delineate the relationship between DC-based immunotherapy and RT. [46] RT combined with CD40 immunotherapy CD40 is a member of the tumor necrosis factor receptor family expressed on APCs, such as B cells, DCs, and macrophages, [47] and its natural ligand CD40L is present on…”
Local Delivery of Immunomodulatory Antibodies for Gastrointestinal Tumors
Silva-Pilipich, N., Covo-Vergara, Á., & Smerdou, C. (2023) · Cancers · doi:10.3390/cancers15082352 · Cited by 5
Turchan, W. T., Pitroda, S. P., & Weichselbaum, R. R. (2022) · Neoplasia · doi:10.1016/j.neo.2022.100782 · Cited by 4
Fibre, microbes and radiotherapy: unravelling the gut’s impact on radiotherapy in cancer
Twhigg, L., Ng, H. M., Glyn, T., Wall, C., & Purcell, R. V. (2025) · ESMO Gastrointestinal Oncology · doi:10.1016/j.esmogo.2025.100174 · Cited by 5
Shi, Y., Liu, L., Wu, J., Gao, M., Sheng, K., Hou, W., Xu, L., & Wang, H. (2025) · Microbiome Research Reports · doi:10.20517/mrr.2025.41 · Cited by 4
Gut microbiota and chemoradiotherapy response in rectal cancer: Biomarker opportunities
Taoum, C., Devaux, A., Rouanet, P., Colombo, P., Boucher, D., & Bonnet, M. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104974 · Cited by 4
Nanotechnology – Microbiota synergy in cancer immunotherapy
Yang, J., Wang, J., Li, J., & Cui, J. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.105018 · Cited by 5
IL-21 enhances the cytotoxicity of intratumoral CD8+ T cells, improving radiation efficacy
Li, X., Xie, X., Wei, B., Sun, X., Chen, M., Liu, R., Tao, Q., Huang, Y., Wang, Q., Ma, S., et al. (2026) · JCI Insight · doi:10.1172/jci.insight.190531 · Cited by 4
“Targeting immune cells, particularly CD8 + T cells, macrophages, and antigen-presenting cells, has shown promise for improving treatment outcomes (11, 35, 36).”
Gut microbial metabolites and immune-related diseases
Guo, J., Yin, X., Wang, K., & Jiang, C. (2026) · Immunity & Inflammation · doi:10.1007/s44466-026-00031-7 · Cited by 6
Timing of thoracic radiotherapy combined with immunotherapy influences pulmonary injury
Yuan, J., Liu, Q., Liu, X., Zheng, X., Nan, X., Shi, X., Zhong, S., Sun, B., Pan, H., Wang, S., et al. (2025) · Oncology Letters · doi:10.3892/ol.2025.14953 · Cited by 3
“Furthermore, it can be employed to generate ‘immunovaccines’ to promote antitumor T cell immune responses (13).”
Interplay between the gut microbiota, its metabolites and carcinogens
Sun, H., Zhai, Q., Liu, J., Shi, K., & Fan, W. (2025) · Clinical & Translational Oncology · doi:10.1007/s12094-025-03920-2 · Cited by 3
“It has been found that vancomycin can affect the gut microbiota directly, thereby potentiating radiotherapy-reduced anti-tumor immune response and regulating antigen presentation in tumors [26].”
Role of the microbiota in oncogenesis
Grigorievskaya, Z. V., Николаевна, П. И., Bagirova, N. S., Агинова, В. В., & Kononets, P. V. (2023) · Siberian Journal of Oncology · doi:10.21294/1814-4861-2023-22-2-129-142 · Cited by 3
Gut microbiota: key facilitator in metastasis of colorectal cancer
Yu, S., Wang, S., Xiong, B., & Peng, C. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1270991 · Cited by 6
Felchle, H., Gissibl, J., Rotgerink, L. L., Nefzger, S. M., Walther, C. N., Timnik, V. R., Combs, S. E., & Fischer, J. C. (2024) · Clinical and Translational Radiation Oncology · doi:10.1016/j.ctro.2024.100758 · Cited by 5
“All in all, supporting literature can be found both for beneficial metabolites (e. g., inosine) associated with enhanced efficacy of ICI monotherapy as well as detrimental metabolites (e.g., butyrate) associated with poorer outcomes after RT monotherapy [19,26,27].”
InfluentialGold digging: Searching for gut microbiota that enhances antitumor immunity
Hou, F., Pan, Z., Yang, R., Zhi, F., & Bi, Y. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.30272 · Cited by 2
Role of Human Microbiome in Development and Management of Head and Neck Squamous Cell Carcinoma
Palkovský, M., Modráčková, N., Bunešová, V., Liberko, M., Hlodáková, A., & Soumarová, R. (2025) · Cancers · doi:10.3390/cancers17132238 · Cited by 2
Focus on gut microbes: new direction in cancer treatment
Liao, L., Zeng, M., Liu, D., He, Y., Du, W., & Cao, Y. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1505656 · Cited by 3
Oral Lachnoanaerobaculum Levels and Survival in Patients With Head and Neck Cancer
Rühle, A., Krausz, M., Ordonez, E. B. M., Heyer, J., Thomsen, A. R., Schäfer, H. S., Kafkaletos, A., Bronsert, P., Kesselring, R., Al‐Ahmad, A., et al. (2025) · JAMA Otolaryngology–Head & Neck Surgery · doi:10.1001/jamaoto.2025.2816 · Cited by 2
Gut microbiota and metabolites: emerging prospects in the treatment of non-small cell lung cancer
Jiao, J.-M., Liu, C., Zang, D., & Chen, J. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1638942 · Cited by 3
The dual roles of microorganisms in inflammatory diseases: initiators and regulators
Liao, Y., Jiang, R., Zhang, H., & Zhang, W. (2026) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2026.2637106 · Cited by 4
“Notably, BUT produced by vancomycin-depleted intestinal bacteria can antagonize the effect of vancomycin [33].”
Tumor-associated bacterial effectors: novel frontiers in tumor biology and immunity
Dai, J.-H., Lu, Y.-Q., Feng, S.-Y., Tan, X.-R., Li, L., Zeng, Y.-C., Chen, J., Ma, J., & Liu, N. (2026) · 中国科学通报:英文版 · doi:10.1016/j.scib.2026.04.034 · Cited by 4
Tan, M.-S., Clister, D., Chandra, Q. M., Wangsa, C. E., Simone, C. N., Umaya, C., Choi, J., Park, S., Rani, A., Akter, S., et al. (2026) · Clinica Chimica Acta · doi:10.1016/j.cca.2026.121086 · Cited by 3
Microbiome therapeutics for the cancer management
Punetha, A., & Punetha, A. K. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-99336-4.00012-4 · Cited by 2
Profir, M., Roşu, O. A., Gașpar, B. S., & Creţoiu, S. M. (2024) · Interdisciplinary cancer research · doi:10.1007/16833_2024_305 · Cited by 4
The microbiome and lung cancer: microbial effects on host immune responses and treatment outcomes
Bailey, A., Leuther, K. K., & Robinson, L. A. (2025) · Frontiers in Microbiomes · doi:10.3389/frmbi.2025.1606551 · Cited by 5
Fidelle, M., Derosa, L., Routy, B., & Zitvogel, L. (2021) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2021.01.022 · Cited by 2
Chen, R., Li, L., & Zhao, W. (2023) · Amino Acids · doi:10.1007/s00726-023-03247-8 · Cited by 2
Acharya, M., Kim, T., & Li, C. (2021) · Cancers · doi:10.3390/cancers13174367 · Cited by 3
“Vancomycin has been shown to increase the activity of radiation therapy [57].”
BackgroundEmerging Role of Gut Microbiome in Cancer Immunotherapy
Bharti, M., Modeel, S., Yadav, S., Yadav, P., Siwach, S., Dolkar, P., Nagar, S., Negi, T., & Negi, R. K. (2023) · Springer eBooks · doi:10.1007/978-981-99-3126-2_18 · Cited by 1
Li, X., Guo, X., Liu, Y., Ren, F., Li, S., Yang, X., Liu, J., & Zhang, Z. (2024) · PLoS ONE · doi:10.1371/journal.pone.0297713 · Cited by 1
Dorobisz, K., Dorobisz, T. A., Pazdro-Zastawny, K., Czyż, K., & Janczak, M. (2024) · Cancers · doi:10.3390/cancers16213707 · Cited by 2
“The modification of the microbiome with antibiotics showed that vancomycin influences a better immune response by reducing the number of bacteria sensitive to vancomycin; the effect of radiotherapy treatment was better after the use of antibiotics [70].”
BackgroundExploiting the endothelial-immune axis to improve radiotherapy efficacy
Guipaud, O., Lago, C., Portier, L., Paget, V., François, A., Supiot, S., & Milliat, F. (2025) · British Journal of Radiology · doi:10.1093/bjr/tqaf114 · Cited by 3
Gut microbiome‐derived metabolites show promise in cancer research and therapy
Yang, K., Wang, Y., Tang, D., Li, P., & Du, L. (2026) · Interdisciplinary medicine · doi:10.1002/inmd.70096 · Cited by 1
Gut microbiota and radiotherapy: towards enhancing radiotherapy efficacy and mitigating toxicities
Li, R., & Huang, J. (2026) · Journal of Holistic Integrative Pharmacy · doi:10.1016/j.jhip.2026.05.007 · Cited by 1
Microbiome dysbiosis and its modulation in cancer development, prevention and therapy
Dixit, S., Welker, A., Ortiz, D., Athanasouli, M., & Stein‐Thoeringer, C. K. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1852716 · Cited by 1
“Furthermore, while systemic SCFAs like butyrate protect the local gut epithelium from radiation toxicity, elevated systemic levels have been shown in some studies to impair cross-priming and abrogate radiation-induced systemic anti-tumor immunity (130, 131).”
del Socorro, T. P., Tonneau, M., Pasquier, D., & Chamaillard, M. (2023) · The Cancer Journal · doi:10.1097/ppo.0000000000000652 · Cited by 1
Gut microbiota in gastric cancer: A determinant of etiology or a therapeutic approach?
Zhang, Y., Cui, M., Zhang, L., Lu, N., Quan, X., Yin, K., Li, A., & Zhang, M. (2023) · World Chinese Journal of Digestology · doi:10.11569/wcjd.v31.i22.933 · Cited by 1
The Microbiome: A New Frontier in Overcoming Drug Resistance in Breast Cancer
Luvhengo, T. E., Miya, T. V., Basera, A., Fadebi, O. O., Mehrotra, R., & Dlamini, Z. (2024) · Springer eBooks · doi:10.1007/978-3-031-52860-6_11 · Cited by 1
Aminzade, Z., Jafari, A., Shirani, A., Karimi, H., Naserpour, M., Javazm, A. R., Shirvani, P., Alijanzadeh, D., Samieefar, N., & Rezaei, N. (2024) · Interdisciplinary cancer research · doi:10.1007/16833_2024_472 · Cited by 1
Nanomedicine-Driven Modulation of the Microbiota for Cancer Therapy
Yan, H., Li, Z., Iqbal, A. Z., Cai, J., Zhao, Y., & Li, C. (2025) · ACS Applied Nano Materials · doi:10.1021/acsanm.5c01345 · Cited by 1
Price, C. A., Nicklin, A. D., Kujawska, M., Koev, T. T., Ilker, N., Fowler, W. J., McKee, A. M., Mitchell, L. J., Rowe, M., Taylor, J. A. G. E., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.09.23.614466 · Cited by 2
“While, microbial metabolites have been most described ( 9, 10, 20, 21 ), emerging research highlights the role of microbial structural compounds, such as pepNdoglycan and exopolysaccharides (EPS), in modulaNng protecNve responses ( 15, 22 ).”
Research Progress of Intestinal Flora and Tumor
黎, 雨. (2020) · Advances in Microbiology · doi:10.12677/amb.2020.94021
The Role of Gut Microbiota Dysbiosis in Gastrointestinal Carcinogenesis
Bartolini, I., & Amedei, A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819265-8.00063-2
Multi-omics Reveal the Enabling Factors of Aplastic AnaemiaPreprint
Zhao, X., Wang, C., Liu, C., Jiang, N., Ding, S., Chen, Y., Yang, L., Liu, C., & Fu, R. (2022) · Research Square · doi:10.21203/rs.3.rs-1313352/v1
Targeting the Gut Microbiome in Cancer Treatment
Čierniková, S., Ševčíková, A., Kasperova, B., Drgoňa, Ľ., & Mego, M. (2022) · Springer eBooks · doi:10.1007/978-3-030-80962-1_263-1
Yi, Y., Shen, L., Shi, W., Xia, F., Zhang, H., Wang, Y., Zhang, J., Wang, Y., Sun, X., Zhang, Z., et al. (2023) · doi:10.1158/1078-0432.c.6529952
Supplementary Data from Microbiota-Centered Interventions: The Next Breakthrough in Immuno-Oncology?
(2023) · doi:10.1158/2159-8290.22540051.v1
The gut microbiota mediates triptolide-induced liver injury via the gut-liver axisPreprint
Wang, Y., Hu, Y., Liu, Y., Zhang, H., Liu, X., Zhou, H., Liu, C., & Yang, T. (2023) · Research Square · doi:10.21203/rs.3.rs-2902171/v1
34 Impact of antibiotic use in the primary treatment of nasopharyngeal carcinoma
Chan, J. Y. K., Chen, Z., & Chen, J. (2024) · Radiotherapy and Oncology · doi:10.1016/s0167-8140(24)00459-6 · Cited by 1
WITHDRAWN: Bacteria beneficially alter the tone of immune responses against tumors
Vitetta, L., & Clarke, S. J. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-14064-8.00008-4
Intestinal Microbiota as a Determinant of Effectiveness and Safety of Anticancer Therapy
Karłowicz-Bodalska, K., Bęben, D., Janicka, N., Gądek, Ł., & Bodalska, G. (2024) · Farmacja Polska · doi:10.32383/farmpol/190217
Ionizing Radiation as a Carcinogen
Jones, J. A., Karouia, F., Cristea, O., Somasundar, T., Popov, D., Hu, Y. F., & Welsh, J. W. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95488-4.00106-6
Simplifying the Biology: Stem, Stroma and Beyond
Saha, S., & Kimler, B. F. (2024) · Springer eBooks · doi:10.1007/978-3-031-47701-0_2
Space Radiation-induced Impacts on Gut Flora, Metabolites and Multisystem Diseases
Zhujun, W. U., Zhang, X., Pang, Y., Yulin, D. E. N. G., & Wang, Z. (2024) · Chinese Journal of Space Science · doi:10.11728/cjss2024.05.2023-0126
Bacteria beneficially alter the tone of immune responses against tumors
Vitetta, L., & Clarke, S. J. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-14064-8.90008-0
Microbiome and colorectal cancer drug resistance
Miya, T. V., Belancio, V. P., & Dlamini, Z. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-33475-7.00016-0
Feigenberg, S. J., Costabile, F., Tanes, C., Bittinger, K. L., O’Connor, R. S., Agarwal, D., Skoufos, G., Salaris, S., Hatzigeorgiou, A. G., Κωστόπουλος, Ν., et al. (2025) · medRxiv · doi:10.1101/2025.01.09.25319989
Self-citationGut microbiota and gastrointestinal tumors: insights from a bibliometric analysis
Chen, C., Wang, X., Han, X., Peng, L., & Zhang, Z. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1558490 · Cited by 1
Association of BCMA-Targeted CAR-T Cell Therapy and the Gut Microbiome in Multiple MyelomaPreprint
Wang, X., Hu, X., Pan, M., Qian, C., Peng, L., Lü, J., Qiang, W., Jin, L., Hao, Y., Chao, Z., et al. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5270396
The Emerging Role of Microbiome in Radiation Research
Alizadeh, P., Mojtahed, A., & Taghizadeh‐Hesary, F. (2025) · Springer eBooks · doi:10.1007/978-3-031-95724-6_19
Jay, S. E., Kabala, Z., Belhouari, M., Bourhafour, M., & Sahraoui, S. (2025) · European Journal of Medical and Health Sciences · doi:10.24018/ejmed.2025.7.5.2326
Faecalcrobiota metabolites: emerging insights into cancer radiotherapy outcomes
Gao, Y., Zeng, B., Wang, Z., Liang, S., & Yang, Y. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1663835 · Cited by 1
Grencewicz, D. J., Loncar, A., Ferrandon, S., Kreamer, M., Chatterjee, D., Mehra, Y., Carson, A., Hoyd, R., Jahanbakhshi, S., Choueiry, F., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.19.677366
Targeting the Gut Microbiome in Cancer Treatment
Čierniková, S., Ševčíková, A., Kasperova, B., Drgoňa, Ľ., & Mego, M. (2025) · Springer eBooks · doi:10.1007/978-3-032-00771-1_263
Feng, X., Wang, X., Luo, S., Zhou, J., & Ke, S. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1719479 · Cited by 2
Then, C., Paillas, S., Moomin, A., Misheva, M., Moir, R., Hay, S. M., Bremner, D. M., Roberts (nee Nellany), K. S., Smith, E. E., Heidari, Z., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25824694
Manipulating gut microbial metabolites for cancer therapy: A metabolism-centric approach
Karne, A. S., Alam, M. I., Tiwari, A., Singh, H., Singh, R. K., & Yadav, A. K. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33459-7.00003-x
Al-Janabi, I. I. (2026) · Al-Rafidain Journal of Medical Sciences · doi:10.54133/ajms.v10i1.2474
“Eradication of Gram-positive bacteria using antibiotics improved the antitumor effects of radiation in melanoma, cervical cancer, and lung cancer in mouse models of these diseases [45,53].”
The hidden mycobiome: emerging role in anticancer immunotherapy
Peng, Z.-C., Liu, X.-Y., Liu, Q.-Y., Lü, W., Jin, C.-Z., Zhang, T.-Y., & Liu, N.-N. (2026) · Mycology: An International Journal on Fungal Biology · doi:10.1080/21501203.2026.2640728
Modulation de l'activation des lymphocytes T et des réponses anti-tumorales par le fer
Porte, S. (2022) · theses.fr (ABES) · doi:10.70675/4251e200zd50ez4a76zb869zb97fa8d3e879
Gut-targeted strategies at the intersection of radiotherapy and immunotherapy
Facciabene, A., & Ellsworth, S. G. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-014211
“…have shown that Gram-positive depletion with oral vancomycin can enhance DC cross-presentation and potentiate RT efficacy, 13 with independent validation that microbiota-derived butyrate suppresses type I interferon and STING (Stimulator of Interferon Genes) signaling, thereby impairing RT…”
Self-citationMetabolomics and proteomics in microbiome-cancer analysis
Bilal, A., Ghani, S., Hasan, A., Husain, H., & Husain, A. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-40551-8.00014-7
Akram, F., Zainab, S., Shabbir, I., & Haq, I. U. (2026) · Folia Microbiologica · doi:10.1007/s12223-026-01515-0
Neutrophil extracellular traps in tumor microenvironment for radiotherapy: friend or foe?
Luo, X., Qi, X., Chang, X., Wang, Z., Liu, R., & Zhao, H. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1638314 · Cited by 1
de Kermenguy, F., Ellsworth, S. G., Facciabene, A., Durante, M., Pacelli, R., St‐Aubin, J., & Wang, D. (2026) · Journal of Applied Clinical Medical Physics · doi:10.1002/acm2.70636
Self-citationRobinson, S. D., Price, C. A., Nicklin, A. D., Kujawska, M., Koev, T. T., Liu, T., Ilker, N., Lumbreras-Perales, C., Teng, N. M. Y., Fowler, W. J., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-9946512/v1
“While, microbial metabolites have been most described 9, 10, 20, 21 , emerging research highlights the role of microbial structural compounds, such as peptidoglycan and exopolysaccharides (EPS), in modulating protective responses 15, 22 .”
Metadata
- Authors
- Uribe-Herranz, M., Rafail, S., Beghi, S., Gil-de-Gómez, L., Verginadis, I., Bittinger, K., Pustylnikov, S., Pierini, S., Perales-Linares, R., Blair, I. A., Mesaros, C. A., Snyder, N. W., Bushman, F., Koumenis, C., & Facciabene, A.
- Affiliations
- University of Pennsylvania (US)
- Children's Hospital of Philadelphia (US)
- Drexel University (US)
- Corresponding author
- Koumenis, Constantinos
- Facciabene, Andrea
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2019-12-09
- Volume
- 130
- Issue
- 1
- Pages
- 466-479
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC6934221
- OpenAlex
- W2993330612
- Cited by
- 316
- References
- 79
- Citations by year
- 2026: 37 · 2025: 59 · 2024: 60 · 2023: 52 · 2022: 44 · 2021: 43 · 2020: 21
- FWCI
- 8.94
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Children's Hospital of Philadelphia
- University of Pennsylvania
- National Institutes of Health
- National Cancer Institute (R01CA116779, R01CA219871)
- National Institute of General Medical Sciences (R01GM132261)
- National Institute of Environmental Health Sciences (P30ES013508)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- gut microbiota, radiotherapy, dendritic cells, antigen presentation, antitumor immunity, vancomycin, butyrate, CD8+ T cells, interferon-gamma, abscopal effect
- MeSH terms
- Gastrointestinal Microbiome, Animals, Antigens, Neoplasm, Butyrates, Dendritic Cells, Female, Neoplasms, Experimental, Antigen Presentation, Mice, Knockout, CD8-Positive T-Lymphocytes, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.